Show simple item record

dc.contributor.authorAleskandarany, MA
dc.contributor.authorGreen, AR
dc.contributor.authorBenhasouna, AA
dc.contributor.authorBarros, FF
dc.contributor.authorNeal, K
dc.contributor.authorReis-Filho, JS
dc.contributor.authorEllis, IO
dc.contributor.authorRakha, EA
dc.date.accessioned2018-08-13T10:15:33Z
dc.date.issued2012
dc.identifier1
dc.identifier.citationBREAST CANCER RESEARCH, 2012, 14
dc.identifier.issn1465-542X
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2313
dc.identifier.doi10.1186/bcr3084
dc.description.abstractIntroduction: Although the prognostic significance of proliferation in early invasive breast cancer has been recognized for a long time, recent gene-expression profiling studies have reemphasized its biologic and prognostic value and the potential application of its assessment in routine practice, particularly to define prognostic subgroups of luminal/hormone receptor-positive (HR+) tumors. This study aimed to assess the prognostic value of a proliferation assay by using Ki-67 immunohistochemistry as compared with mitotic count scores. Method: Proliferation was assessed by using Ki-67 labeling index (Ki-67LI) and mitotic scores in a large (n = 1,550) and well-characterized series of clinically annotated primary operable invasive breast cancer with long-term follow-up. Tumors were phenotyped based on their IHC profiles into luminal/HR+, HER2(+), and triple-negative (TN) classes. We used a split-sample development and validation approach to determine the optimal Ki-67LI cut-offs. Results: The optimal cut-points of Ki-67LI were 10% and 50% for the luminal class. Both Ki7LI and MS were able to split luminal tumors into subgroups with significantly variable outcomes, independent of other variables. Neither mitotic count scores nor Ki-67LI was associated with outcome in the HER2(+) or the TN classes. Conclusions: Assessment of proliferation by using Ki-67LI and MS can distinguish subgroups of patients within luminal/hormone receptor-positive breast cancer significantly different in clinical outcomes. Overall, both Ki-67 LI and mitotic-count scores showed comparable results. The method described could provide a cost-effective method for prognostic subclassification of luminal/hormone receptor-positive breast cancer in routine clinical practice.
dc.languageeng
dc.language.isoeng
dc.publisherBIOMED CENTRAL LTD
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titlePrognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer
dc.typeJournal Article
rioxxterms.versionofrecord10.1186/bcr3084
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2012
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfBREAST CANCER RESEARCH
pubs.notesaffiliation: Rakha, EA (Reprint Author), Univ Nottingham, Queens Med Ctr, Sch Mol Med Sci, Dept Histopathol, Nottingham NG7 2UH, England. Aleskandarany, Mohammed A.; Green, Andrew R.; Benhasouna, Ahmed A.; Barros, Fabricio F.; Ellis, Ian O.; Rakha, Emad A., Univ Nottingham, Queens Med Ctr, Sch Mol Med Sci, Dept Histopathol, Nottingham NG7 2UH, England. Aleskandarany, Mohammed A.; Green, Andrew R.; Benhasouna, Ahmed A.; Barros, Fabricio F.; Neal, Keith; Ellis, Ian O.; Rakha, Emad A., Nottingham Univ Hosp NHS Trust, Nottingham NG7 2UH, England. Aleskandarany, Mohammed A., Menoufia Univ, Fac Med, Dept Pathol, Shibin Al Kawm, Menoufia Govern, Egypt. Reis-Filho, Jorge S., Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England. article-number: R3 keywords-plus: HISTOLOGIC GRADE; CELL PROLIFERATION; MITOTIC-ACTIVITY; IN-SITU; EXPRESSION; CARCINOMA; SUBTYPES; CHEMOTHERAPY; PHENOTYPE; PATHOLOGY research-areas: Oncology web-of-science-categories: Oncology author-email: [email protected] researcherid-numbers: Aleskandarany, Mohammed/D-9162-2018 orcid-numbers: Aleskandarany, Mohammed/0000-0001-5538-5946 Rakha, Emad/0000-0002-5009-5525 Ellis, Ian/0000-0001-5292-8474 Green, Andrew/0000-0002-0488-5913 funding-acknowledgement: University of Nottingham; Nottingham University Hospitals Trust; Ministry of Higher Education (Egypt); Breast Cancer Campaign funding-text: We acknowledge the support of the University of Nottingham and Nottingham University Hospitals Trust in funding EA Rakha and IO Ellis. We thank the Ministry of Higher Education (Egypt) for funding MA Aleskandarany, and the Breast Cancer Campaign for funding AR Green. number-of-cited-references: 37 times-cited: 55 usage-count-last-180-days: 0 usage-count-since-2013: 6 journal-iso: Breast Cancer Res. doc-delivery-number: 987UU unique-id: ISI:000307444100012 oa: gold_or_bronze da: 2018-08-13
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Molecular Pathology
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Molecular Pathology
pubs.volume14
pubs.embargo.termsNot known
icr.researchteamMolecular Pathologyen_US
dc.contributor.icrauthorReis-Filho, Jorge Sergioen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0